Mazindol combination in the treatment of attention-deficit/hyperactivity

Abstract

The present invention relates to the field of human health, and more particularly to the treatment of attention deficit/hyperactivity disorder (ADHD) with mazindol. The latter can be administered as monotherapy or in combination with one or more compounds, including psychostimulants, for the indication of ADHD and associated or co-morbid symptoms.

1 . A method for the preventive and/or curative treatment of attention-deficit/hyperactivity disorder (ADHD) or at least one of the symptoms thereof, comprising the administration of an effective amount of mazindol to a patient in need of such treatment. 
     
     
         2 - 15 . (canceled) 
     
     
         16 . The method according to  claim 1 , wherein said patient is chosen from a newborn baby, a child, an adolescent or an adult. 
     
     
         17 . The method according to claim  2 , wherein said patient is a child having isolated iron deficiency, but not anaemic. 
     
     
         18 . The method according to  claim 1 , wherein mazindol is formulated to allow its administration by oral, anal, parenteral, intra-muscular or intravenous method. 
     
     
         19 . The method according to  claim 1 , wherein the symptoms are selected from inattention, impulsivity, impatience, daytime or nighttime motor hyperactivity, insomnia and restless legs syndrome. 
     
     
         20 . The method according to  claim 1 , wherein mazindol is administrated simultaneously, separately or sequentially with iron. 
     
     
         21 . The method according to  claim 1 , wherein mazindol is administrated simultaneously, separately or sequentially with at least one compound selected from psychostimulants. 
     
     
         22 . The method according to  claim 21 , wherein said compound is chosen from methylphenidate, modafinil, atamoxetine, amphetamines, in particular d-amphetamine, dexedrine, dexamphetamine, L-Dopa, dopamine, and dopamine agonists. 
     
     
         23 . The method according to  claim 1 , wherein the dosage corresponds to a daily dose of mazindol of between 1 and 2 mg. 
     
     
         24 . The method according to  claim 1 , wherein said patient suffers from ferritin deficiency, said serum ferritin concentration of said patient being less than 50 μg/litre, less than approximately 40 μg/l, less than approximately 35 μg/l, less than approximately 30 μg/l, less than approximately 20 μg/l, less than approximately 15 g/l, less than approximately 10 g/l or less than approximately 5 μg/l. 
     
     
         25 . The method according to  claim 24 , wherein said patient also has a normal serum concentration of transferrin-soluble receptors. 
     
     
         26 . The method according to  claim 1  for the preventive treatment of a newborn, adolescent or young adult patient liable to develop a neurodegenerative pathology at an adult age, wherein said newborn, adolescent or young adult patient has at least one of the following symptoms:
 a ferritin deficiency, so that the serum ferritin concentration is less than 50 μg/l, 
 a normal serum concentration of transferrinsoluble receptors, 
 attention-deficit/hyperactivity disorder, or at least one of the symptoms thereof. 
 
     
     
         27 . The method according to  claim 26 , wherein said neurodegenerative pathology is Parkinson's disease. 
     
     
         28 . Pharmaceutical composition comprising pharmaceutically acceptable excipients and mazindol. 
     
     
         29 . Composition according to  claim 28 , further comprising iron or one of its pharmaceutically acceptable salts and/or a psychostimulant.